Foghorn Therapeutics (FHTX) Cash from Investing Activities (2019 - 2026)

Foghorn Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$17.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 160.27% year-over-year to -$17.7 million; the TTM figure through Mar 2026 stood at $64.9 million (up 335.23% YoY), while the FY2025 annual figure was $112.0 million, up 474.67% from the prior year.
• Cash from Investing Activities was -$17.7 million for Q1 2026 at Foghorn Therapeutics, down from $13.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $46.1 million in Q3 2022 to a low of -$159.4 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$2.1 million across 5 years, with a median of $27.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 4788.35% in 2022, then soared 674.54% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$6.5 million in 2022, then jumped by 674.54% to $37.4 million in 2023, then slumped by 40.37% to $22.3 million in 2024, then tumbled by 40.64% to $13.2 million in 2025, then slumped by 233.91% to -$17.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$17.7 million (Q1 2026), $13.2 million (Q4 2025), and $35.6 million (Q3 2025), per Business Quant data.